Clinical TopicsHome Page Recent ArticlesNews

New treatment for acute hepatic porphyria

By: Lydia L. Kim, Digital Content Editor

The U.S. Food and Drug Administration (FDA) recently granted approval to Alnylam Pharmaceuticals’ givosiran (Givlaari), a new treatment for adult patients with acute hepatic porphyria (AHP).   

AHP is a genetic disorder that manifests as a “buildup of toxic porphyrin molecules” that form “during the production of heme (which helps bind oxygen to the blood).” The director of the FDA’s Oncology Center of Excellence, Richard Pazdur, MDsummarizes the impact of these symptoms on patients: “This buildup can cause acute attacks, known as porphyria attacks, which can lead to severe pain and paralysis, respiratory failure, seizures, and mental status changes. These attacks occur suddenly and can produce permanent neurological damage and death.” 

 In a clinical trial involving 94 patients, givosiran was shown to reduce the frequency of porphyria attacks, thus increasing patients’ quality of life. Givosiran previously received its FDA orphan drug designation, so its approval is especially exciting for the AHP community. 

 Please read more about the approval here 



The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal. This has not been peer reviewed.

1 Comment. Leave new

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.


More Perspectives